中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents

Research advances in post-sinusoidal non-cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.07.004
Research funding:

National Natural Science Foundation of China (81970507);

National Natural Science Foundation of China (82170585);

Natural Science Foundation of Guangdong Province (2020A1515010100);

Natural Science Foundation of Guangdong Province (2021A1515011290);

Technology Planning Project of Guangzhou City (201904010132);

Technology Planning Project of Guangzhou City (202102010023);

Guangdong Medical Science and Research Foundation (A2020411);

Guangzhou High Technology Project (2019GX05);

Project of Key Medical Discipline in Guangzhou (2021-2023)

More Information
  • Corresponding author: ZHOU Yongjian, eyzhouyongjian@scut.edu.cn(ORCID: 0000-0002-4036-4592)
  • Received Date: 2022-04-20
  • Accepted Date: 2022-05-22
  • Published Date: 2022-07-20
  • Portal hypertension (PH) is defined as the pathological increase in pressure in the portal venous system. The most common cause of PH is liver cirrhosis, but it is also observed in patients without liver cirrhosis, which is called non-cirrhotic portal hypertension. Non-cirrhotic portal hypertension can be classified in prehepatic, intrahepatic, and posthepatic types depending on the site of involvement, and the intrahepatic type can be further divided into presinusoidal, sinusoidal, and post-sinusoidal types. This article summarizes the features of posthepatic and post-sinusoidal portal hypertension, discusses in detail the different classifications of Budd-Chiari syndrome and hepatic sinusoidal obstruction syndrome, and briefly introduces the research advances in the clinical manifestations, pathogenesis, diagnosis, and treatment of these diseases.

     

  • loading
  • [1]
    MAROZAS M, ZYKUS R, SAKALAUSKAS A, et al. Noninvasive evaluation of portal hypertension using a supervised learning technique[J]. J Healthc Eng, 2017, 2017: 6183714. DOI: 10.1155/2017/6183714.
    [2]
    MAHMOUD AE, ELIAS E, BEAUCHAMP N, et al. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis[J]. Gut, 1997, 40(6): 798-800. DOI: 10.1136/gut.40.6.798.
    [3]
    PLESSIER A, VALLA DC. Budd-Chiari syndrome[J]. Semin Liver Dis, 2008, 28(3): 259-269. DOI: 10.1055/s-0028-1085094.
    [4]
    BOLONDI L, GAIANI S, LI BASSI S, et al. Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound[J]. Gastroenterology, 1991, 100(5 Pt 1): 1324-1331.
    [5]
    SOYER P, RABENANDRASANA A, BARGE J, et al. MRI of Budd-Chiari syndrome[J]. Abdom Imaging, 1994, 19(4): 325-329. DOI: 10.1007/BF00198189.
    [6]
    XU P, LYU L, SAMI MU, et al. Diagnostic accuracy of magnetic resonance angiography for Budd-Chiari syndrome: A meta-analysis[J]. Exp Ther Med, 2018, 16(6): 4873-4878. DOI: 10.3892/etm.2018.6764.
    [7]
    TANG TJ, BATTS KP, de GROEN PC, et al. The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome[J]. J Hepatol, 2001, 35(3): 338-343. DOI: 10.1016/s0168-8278(01)00131-3.
    [8]
    RAUTOU PE, MOUCARI R, CAZALS-HATEM D, et al. Levels and initial course of serum alanine aminotransferase can predict outcome of patients with Budd-Chiari syndrome[J]. Clin Gastroenterol Hepatol, 2009, 7(11): 1230-1235. DOI: 10.1016/j.cgh.2009.06.011.
    [9]
    LI Z, WANG L, YI F, et al. Rapid development of gingival bleeding after rivaroxaban in a patient with Budd-Chiari syndrome[J]. Liver Int, 2021, 41(9): 2236-2237. DOI: 10.1111/liv.15021.
    [10]
    DARWISH MURAD S, PLESSIER A, HERNANDEZ-GUERRA M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome[J]. Ann Intern Med, 2009, 151(3): 167-175. DOI: 10.7326/0003-4819-151-3-200908040-00004.
    [11]
    HAN G, QI X, ZHANG W, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center[J]. Radiology, 2013, 266(2): 657-667. DOI: 10.1148/radiol.12120856.
    [12]
    MENTHA G, GIOSTRA E, MAJNO PE, et al. Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres[J]. J Hepatol, 2006, 44(3): 520-528. DOI: 10.1016/j.jhep.2005.12.002.
    [13]
    Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.

    中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
    [14]
    YANG M, RUAN J, GAO H, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans[J]. Arch Toxicol, 2017, 91(12): 3913-3925. DOI: 10.1007/s00204-017-2013-y.
    [15]
    KERNAN N, RICHARDSON P, TRIPLETT B, et al. Efficacy and safety of defibrotide (DF) to treat hepatic veno-occlusive di sease/ sinusoidal obstruction svndrome (VOD/SOS) after primarv chemotherapv(CT): A post hocanalysis of final data[J]. J Clin Oncol, 2017, 35(15): 10513. DOI: 10.1200/jco.2017.35.15_supp.10513.
    [16]
    XIA Y, QIN H, YANG J. Hepatic veno-occlusive disease development in the hematopoietic stem cell transplantation patients: incidence and associated risk factors, a meta-analysis[J]. Eur J Gastroenterol Hepatol, 2021, 33(6): 872-884. DOI: 10.1097/MEG.0000000000001802.
    [17]
    MOHTY M, MALARD F, ABECASSIS M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2016, 51(7): 906-912. DOI: 10.1038/bmt.2016.130.
    [18]
    DEVARBHAVI H, SINGH R, PATE M, et al. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury[J]. J Gastroentero Hepatol, 2013, 28(1): 161-167. DOI: 10.1111/j.1440-1746.2012.07279.x.
    [19]
    KIM J, JUNG Y. Radiation—induced liver disease: Current understanding and future perspectives[J]. Exp Mol Med, 2017, 49(7): e359. DOI: 10.1038/emm.2017.85.
    [20]
    YOON JH, MIN GJ, PARK SS, et al. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1[J]. Bone Marrow Transplant, 2021, 56(7): 1603-1613. DOI: 10.1038/s41409-021-01215-y.
    [21]
    MOHTY M, MALARD F, ABECASIS M, et al. Prophylactic, preemptive, and curative treatment for sinusoia-l obstruction syndrome/venoocclusive disease in adult patients: a position statement from an international expert group[J]. Bone Marrow Transplant, 2020, 55(3): 485-495. DOI: 10.1038/s41409-019-0705-z.
    [22]
    DIGNAN FL, WYNN RF, HADZIC N, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J]. Br J Haematol, 2013, 163(4): 444-457. DOI: 10.1111/bjh.12558.
    [23]
    PICOD A, BONNIN A, BATTIPAGLIA G, et al. Defibrotide for sinusoidal obstruction syndrome/veno-occlusive disease prophylaxis in high-risk adult patients: a single-center experience study[J]. Biol Blood Marrow Transplant, 2018, 24(7): 1471-1475. DOI: 10.1016/j.bbmt.2018.02.015.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Article Metrics

    Article views (641) PDF downloads(115) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return